Harrow has announced an exclusive out-licensing agreement with Apotex, a major Canadian pharmaceutical company, to market and distribute five of the company’s branded ophthalmic products.
“We are pleased to enter the Canadian market through this partnership with Apotex, which has a proven track record of success serving Canadian eye care professionals and their patients,” Mark L. Baum, Harrow chairman and CEO, said in a company press release. “This exclusive agreement fulfills our commitment to access and availability of these five important ophthalmic pharmaceutical